Educational article
Carbapenems
Carbapenems are broad-spectrum β-lactams stable against many, but not all, β-lactamases. Meropenem, imipenem and ertapenem differ in spectrum and pharmacokinetics. Broad activity does not mean activity against every…
Overview
Carbapenems are broad-spectrum β-lactams stable against many, but not all, β-lactamases. Meropenem, imipenem and ertapenem differ in spectrum and pharmacokinetics. Broad activity does not mean activity against every microorganism.
Biology and practical meaning
Carbapenem resistance can arise from a carbapenemase or from other β-lactamases combined with impaired entry. Distinguishing these causes supports surveillance and additional testing. A negative limited gene panel does not exclude a resistant phenotype.
Spectrum, exposure and AST
Spectrum describes the range of organisms an agent can act against; activity against a particular isolate is assessed separately. Access to the target, target changes, enzymes and efflux can alter activity. Agents in the same class are not completely interchangeable.
Pharmacokinetics describes distribution and elimination; pharmacodynamics links exposure to effect. Blood concentrations and exposure at the infection site can differ. A lower MIC number for a different antibiotic therefore does not establish superior clinical activity.
S, I and R are interpreted using a current standard for the organism–agent pair. Under EUCAST, I means susceptible with increased exposure. It does not mean resistant and does not independently specify a treatment regimen. Decisions also depend on the site, patient, contraindications, interactions and current guidance. This article explains mechanisms and terminology. The 2025 AWaRe classification concerns use policy, while the 2022 AWaRe book has subsequent updates; neither replaces an individual AST result.
Sources
Read next
Educational material from AMR Atlas. Does not replace clinical guidance or laboratory procedures.